Latest News and Press Releases

Wilmington, Delaware, United States, Sept. 25, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The warts therapeutics market was estimated to have acquired US$ 1.92 billion in 2018.  It...

Dublin, March 24, 2023 (GLOBE NEWSWIRE) -- The "Dermatology Devices Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.The global dermatology devices market grew...

Dublin, Feb. 03, 2023 (GLOBE NEWSWIRE) -- The "Global Dermatoscope Market by Product, Technology, Modality, Application, End-user, Region: Competition Forecast and Opportunities to 2027" report has...

New York, March 25, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Dermatology OTC Medications Market Forecast to 2028 - COVID-19 Impact and Global Analysis By...

Dublin, Nov. 26, 2021 (GLOBE NEWSWIRE) -- The "Global Light Activated Therapies Market: Distribution by Target Indications, Key Players and Geographies: Industry Trends and Global Forecasts,...

Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...

MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical...

Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...

MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the...

MORRISVILLE, N.C., March 01, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that preclinical data demonstrating the anti-viral effects of the Company’s...